Showing results (91-100 of 323) with videos related to

Sort By:
Pageof 33
Thoracic Cancer|August 18, 2023
Role of prognostic nutritional index in postoperative radiotherapy for non-small cell lung cancerHyejo Ryu, Changhoon Song, Jae-Sung Kim, et al.
Translational Cancer Research|February 4, 2022
Antitumor activity and safety of sirolimus for solid tumors with PIK3CA mutations: A multicenter, open-label, prospective single-arm study (KM 02-01, KCSG UN17-16)Seonggyu Byeon, Myoung Joo Kang, Yoon Ji Choi, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|October 10, 2018
Increased CD3+ T cells with a low FOXP3+/CD8+ T cell ratio can predict anti-PD-1 therapeutic response in non-small cell lung cancer patientsHyojin Kim, Hyun Jung Kwon, Yeon Bi Han, et al.
Radiation Oncology (London, England)|October 8, 2011
The prognostic value of the nodal ratio in N1 breast cancerTae Jin Han, Eun Young Kang, Wan Jeon, et al.
Medical Oncology (Northwood, London, England)|June 10, 2010
Biomarker analysis in patients with advanced gastric cancer treated with S-1 plus cisplatin chemotherapy: orotate phosphoribosyltransferase expression is associated with treatment outcomesIn Sil Choi, Hye Seung Lee, Keun-Wook Lee, et al.
Journal of Cancer Research and Clinical Oncology|November 21, 2014
Current status of chemotherapy use and clinical outcome in octogenarians with advanced non-small cell lung cancerSung Hoon Sim, Yu Jung Kim, Se Hyun Kim, et al.
World Journal of Surgical Oncology|February 14, 2014
Preoperative thrombocytosis is a significant unfavorable prognostic factor for patients with resectable non-small cell lung cancerMiso Kim, Hyun Chang, Hee Chul Yang, et al.
International Journal of Oncology|December 22, 2007
Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatinSun Young Kim, Hwang Phill Kim, Yu Jung Kim, et al.
Scientific Reports|May 20, 2024
Machine learning-based model to predict delirium in patients with advanced cancer treated with palliative care: a multicenter, patient-based registry cohortYu Jung Kim, Hayeon Lee, Ho Geol Woo, et al.
JAMA Oncology|November 26, 2025
Lorlatinib in Tyrosine Kinase Inhibitor-Naive Advanced ROS1-Positive Non-Small Cell Lung Cancer: A Phase 2 Nonrandomized Clinical TrialBeung Chul Ahn, Yu Jung Kim, Youngjoo Lee, et al.
Pageof 33